| Q36944006 | CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype |
| Q24317436 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A |
| Q42324494 | Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. |
| Q42132693 | Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma |
| Q37685527 | Genotypes Affecting the Pharmacokinetics of Anticancer Drugs |
| Q36729190 | Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers |
| Q43087872 | Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers |
| Q36653603 | Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? |
| Q39531106 | Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro |
| Q26799238 | Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine |
| Q37613529 | Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment |
| Q33649116 | No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma |
| Q35584977 | Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism |
| Q37162141 | Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test |
| Q35537682 | Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity |
| Q26830005 | The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy |